The federal government has decided against procuring a protein-based COVID-19 vaccine for the fall immunization campaign — despite it being the only type that some immunocompromised people say they have been able to tolerate.
While the mRNA vaccines made by Pfizer and Moderna are effective at preventing severe illness, hospitalization and death, some people with autoimmune diseases say the jabs can come with a terrible trade-off.
Comments closedLinda Wilhelm, 64, of Bloomfield, N.B., is planning a road trip to the United States. But it’s not to go sightseeing or shopping.
Wilhelm, who suffers from severe rheumatoid arthritis, hopes to get the updated Novavax COVID-19 vaccine, which won’t be available in Canada as part of the fall vaccination campaign, unless provinces and territories order doses on their own.
Wilhelm, president of the Canadian Arthritis Patient Alliance and a member of the Canadian Immunocompromised Advocacy Network, says the protein-based vaccine is a better option for immunocompromised people like her than the more common Pfizer-BioNTech and Moderna mRNA vaccines. She says she feels “expendable” and urges the federal government to reconsider.
Less than two months ago, the network wrote to numerous federal, provincial and territorial officials, calling for improved access to Novavax and increased awareness.
Comments closed✉️ Send letters to PHAC and health ministers to voice your support for access to the Novavax COVID-19 vaccine this fall. Use our online tool to send emails.
Comments closedThe US Food and Drug Administration is poised to sign off as soon as next week on updated Covid-19 vaccines targeting more recently circulating strains of the virus, according to two sources familiar with the matter, as the country experiences its largest summer wave in two years.
The agency is expected to greenlight updated mRNA vaccines from Moderna and Pfizer/BioNTech that target a strain of the virus called KP.2, said the sources, who declined to be named because the timing information isn’t public. It was unclear whether the agency simultaneously would authorize Novavax’s updated shot, which targets the JN.1 strain.
The move would be several weeks ahead of last year’s version of the vaccine, which got FDA signoff on September 11.
Comments closedCanada’s National Advisory Committee on Immunization says some groups of people vulnerable to severe illness from COVID-19 should be eligible for another dose of vaccine in the spring.
The recommendation issued Friday says people aged 65 and older, residents of long-term care homes and seniors living in other congregate settings may get another shot of the vaccine targeted to the XBB.1.5 variant.
It also says children and adults aged six months and older who are moderately to severely immunocompromised due to an underlying condition may also get the booster.
Comments closed
